Somatic/JJ
Mutations/NNS
from/IN
Whole/JJ
Exome/NN
Sequencing/NN
Analysis/NN
of/IN
the/DT
Patients/NNS
with/IN
Biliary/JJ
Tract/JJ
Cancer/NN
./.
====================
Biliary/JJ
tract/NN
cancer/NN
(/(
BTC/NN
)/)
is/VBZ
a/DT
rare/JJ
cancer/NN
and/CC
is/VBZ
associated/VBN
with/IN
a/DT
poor/JJ
prognosis/NN
./.
====================
To/TO
understand/VB
the/DT
genetic/JJ
characteristics/NNS
of/IN
BTC/NN
,/,
we/PRP
analyzed/VBD
whole-exome/DT
sequencing/NN
data/NNS
and/CC
identified/VBD
somatic/JJ
mutations/NNS
in/IN
patients/NNS
with/IN
BTC/NN
./.
====================
Tumors/NNS
and/CC
matched/VBN
blood/NN
or/CC
normal/JJ
samples/NNS
were/VBD
obtained/VBN
from/IN
seven/CD
patients/NNS
with/IN
cholangiocarcinoma/NN
who/WP
underwent/JJ
surgical/JJ
resection/NN
./.
====================
We/PRP
discovered/VBD
inactivating/VBG
mutations/NNS
of/IN
tumor/NN
suppressor/NN
genes/NNS
,/,
including/VBG
APC/NN
,/,
TP53/NN
,/,
and/CC
ARID1A/NN
,/,
in/IN
three/CD
patients/NNS
./.
====================
Activating/VBG
mutations/NNS
of/IN
KRAS/JJ
and/CC
NRAS/NN
were/VBD
also/RB
identified/VBD
./.
====================
Our/PRP$
analyses/NNS
identified/VBD
somatic/JJ
mutations/NNS
in/IN
Korean/JJ
patients/NNS
with/IN
BTC/NN
./.
====================
Biliary/JJ
tract/NN
cancer/NN
(/(
BTC/NN
)/)
is/VBZ
a/DT
heterogeneous/JJ
group/NN
of/IN
cancers/NNS
,/,
including/VBG
gallbladder/NN
cancer/NN
and/CC
extrahepatic/JJ
and/CC
intrahepatic/JJ
cholangiocarcinoma/NN
./.
====================
BTC/NN
has/VBZ
been/VBN
known/VBN
as/IN
a/DT
disease/NN
with/IN
a/DT
poor/JJ
prognosis/NN
,/,
with/IN
few/JJ
treatment/NN
options/NNS
,/,
regardless/RB
of/IN
its/PRP$
low/JJ
incidence/NN
./.
====================
In/IN
Korea/NN
,/,
in/IN
2014/CD
,/,
the/DT
crude/JJ
incidence/NN
rate/NN
of/IN
BTC/NN
was/VBD
11.2/CD
per/IN
100,000/CD
men/NNS
,/,
and/CC
the/DT
crude/JJ
mortality/NN
rate/NN
was/VBD
7.7/CD
per/IN
100,000/CD
in/IN
both/DT
men/NNS
and/CC
women/NNS
[/(
1/CD
]/)
./.
====================
Most/JJS
patients/NNS
have/VBP
been/VBN
diagnosed/VBN
at/IN
an/DT
advanced/JJ
stage/NN
./.
====================
Although/IN
surgical/JJ
resection/NN
is/VBZ
a/DT
curative/JJ
treatment/NN
,/,
recurrence/NN
of/IN
disease/NN
has/VBZ
been/VBN
a/DT
clinical/JJ
issue/NN
for/IN
patients/NNS
after/IN
surgery/NN
[/(
2/CD
]/)
./.
====================
Combination/NN
treatment/NN
with/IN
cisplatin/NN
plus/CC
gemcitabine/NN
has/VBZ
been/VBN
reported/VBN
as/IN
an/DT
appropriate/JJ
treatment/NN
for/IN
patients/NNS
with/IN
advanced/JJ
BTC/NN
[/(
3/CD
]/)
./.
====================
The/DT
genomic/JJ
characteristics/NNS
of/IN
BTC/NN
have/VBP
been/VBN
revealed/VBN
through/IN
several/JJ
studies/NNS
using/VBG
high-throughput/JJ
next-generation/NN
sequencing/NN
technologies/NNS
[/(
4–6/CD
]/)
./.
====================
Jiao/NN
et/FW
al/JJ
./.
====================
[/(
5/CD
]/)
reported/VBD
exome/JJ
sequencing/NN
results/NNS
of/IN
32/CD
patients/NNS
with/IN
intrahepatic/JJ
cholangiocarcinoma/NN
./.
====================
Inactivating/VBG
mutations/NNS
in/IN
chromatin/NN
remodeling/NN
genes/NNS
,/,
including/VBG
BAP1/NN
,/,
ARID1A/NN
,/,
and/CC
PBRM1/NN
,/,
were/VBD
identified/VBN
with/IN
frequent/JJ
mutations/NNS
in/IN
IDH1/NN
and/CC
IDH2/NN
./.
====================
The/DT
oncogenes/NNS
KRAS/NN
,/,
PIK3CA/NN
,/,
NRAS/NN
,/,
GNAS/NN
,/,
and/CC
ERBB2/NN
were/VBD
also/RB
significantly/RB
mutated/VBN
in/IN
BTC/NN
[/(
6/CD
]/)
./.
====================
Genomic/JJ
analyses/NNS
need/VBD
to/TO
be/VB
performed/VBN
in/IN
more/RBR
BTCs/NNS
to/TO
understand/VB
their/PRP$
biology/NN
and/CC
develop/VBP
therapeutic/JJ
strategies/NNS
./.
====================
Here/RB
,/,
we/PRP
reported/VBD
the/DT
whole-exome/JJ
sequencing/NN
(/(
WES/NNS
)/)
data/NNS
of/IN
seven/CD
patients/NNS
with/IN
BTC/NN
and/CC
analyzed/VBD
their/PRP$
somatic/JJ
mutations/NNS
to/TO
compare/VB
the/DT
genetic/JJ
features/NNS
between/IN
patients/NNS
./.
====================
Patients/NNS
and/CC
ppub/NN
of/IN
clinical/JJ
data/NNS
====================
All/DT
patients/NNS
had/VBD
been/VBN
enrolled/VBN
in/IN
a/DT
phase/NN
II/CD
clinical/JJ
trial/JJ
at/IN
the/DT
National/JJ
Cancer/NN
Center/NN
of/IN
Korea/NN
,/,
as/IN
approved/JJ
by/IN
the/DT
institutional/JJ
review/NN
board/IN
(/(
IRB/NN
No/DT
./.
====================
NCCCTC-09-411/NN
)/)
./.
====================
Enrolled/VBN
patients/NNS
had/VBD
undergone/NN
surgical/JJ
resection/NN
for/IN
BTC/NN
and/CC
were/VBD
then/RB
treated/VBN
with/IN
gemcitabine/NN
(/(
1,000/CD
mg/m2/NN
)/)
as/IN
an/DT
adjuvant/JJ
chemotherapy/NN
./.
====================
The/DT
participants/NNS
voluntarily/RB
agreed/RB
to/TO
donate/VB
the/DT
materials/NNS
by/IN
signing/VBG
an/DT
informed/VBN
consent/NN
form/VBP
./.
====================
Tumor/NN
samples/NNS
were/VBD
obtained/VBN
from/IN
surgical/JJ
specimens/NNS
and/CC
blood/NN
from/IN
seven/CD
patients/NNS
with/IN
BTC/NN
./.
====================
Whole-exome/DT
sequencing/NN
and/CC
data/NNS
analysis/NN
====================
We/PRP
extracted/VBD
genomic/JJ
DNA/NN
from/IN
tissue/NN
specimens/NNS
and/CC
blood/NN
samples/NNS
using/VBG
the/DT
QIAamp/NN
DNA/NN
mini/NNS
kit/NN
according/VBG
to/TO
the/DT
manufacturer/NN
’/CD
s/NNS
protocol/NN
(/(
Qiagen/NN
,/,
Valencia/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
./.
====================
The/DT
concentration/NN
and/CC
quality/NN
of/IN
DNA/NN
were/VBD
assessed/VBN
using/VBG
a/DT
NanoDrop/JJ
spectrophotometer/NN
(/(
Thermo/DT
Fisher/RB
Scientific/JJ
,/,
Waltham/NN
,/,
MA/NN
,/,
USA/NN
)/)
./.
====================
WES/NNS
was/VBD
performed/VBN
using/VBG
the/DT
SureSelect/NN
Human/JJ
All/DT
Exon/NN
V5/NN
Target/NN
Enrichment/JJ
kit/NN
(/(
Agilent/JJ
Technologies/NNS
,/,
Santa/NN
Clara/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
and/CC
processed/VBN
on/IN
the/DT
HiSeq/JJ
2500/CD
platform/NN
(/(
Illumina/NN
,/,
San/NNP
Diego/JJ
,/,
CA/NNP
,/,
USA/NNP
)/)
./.
====================
The/DT
size/NN
and/CC
quantity/NN
of/IN
the/DT
libraries/NNS
were/VBD
checked/VBN
using/VBG
a/DT
2100/CD
Bioanalyzer/NNP
(/(
Agilent/JJ
Technologies/NNS
)/)
./.
====================
Sequence/NN
reads/VBZ
were/VBD
aligned/VBN
to/TO
the/DT
human/JJ
reference/NN
genome/NN
hg19/NN
using/VBG
the/DT
Burrows-Wheeler/NN
Aligner–MEM/NN
algorithm/NN
[/(
7/CD
]/)
./.
====================
The/DT
alignments/NNS
were/VBD
refined/VBN
using/VBG
the/DT
Genome/NN
Analysis/NN
Tool/NN
Kit/NN
(/(
Broad/JJ
Institute/JJ
)/)
,/,
and/CC
duplicate/JJ
or/CC
low-quality/JJ
reads/VBZ
were/VBD
excluded/VBN
[/(
8/CD
]/)
./.
====================
Somatic/JJ
mutations/NNS
were/VBD
called/VBN
using/VBG
Mutect/JJ
and/CC
Strelka/NN
with/IN
default/NN
settings/NNS
by/IN
comparing/VBG
the/DT
sequences/NNS
of/IN
tumor/NN
samples/NNS
with/IN
those/DT
of/IN
matched/VBN
normal/JJ
samples/NNS
[/(
9/CD
,/,
10/CD
]/)
./.
====================
Only/RB
mutations/NNS
showing/VBG
a/DT
total/JJ
read/VBN
depth/NN
of/IN
greater/JJR
than/IN
30/CD
in/IN
normal/JJ
samples/NNS
were/VBD
considered/VBN
for/IN
further/JJ
analysis/NN
./.
====================
The/DT
demographic/JJ
and/CC
clinical/JJ
characteristics/NNS
of/IN
the/DT
patients/NNS
with/IN
BTC/NN
,/,
including/VBG
age/NN
,/,
sex/NN
,/,
cancer/NN
stage/NN
,/,
recurrence/NN
,/,
and/CC
survival/NN
,/,
are/VBP
summarized/VBN
in/IN
Table/JJ
1/CD
./.
====================
The/DT
patients/NNS
included/VBD
three/CD
females/NNS
and/CC
four/CD
males/NNS
with/IN
an/DT
average/NN
age/NN
of/IN
60/CD
years/NNS
./.
====================
Among/IN
the/DT
seven/CD
patients/NNS
,/,
five/CD
patients/NNS
were/VBD
defined/VBN
as/IN
experiencing/VBG
recurrence/NN
of/IN
disease/NN
after/IN
surgery/NN
./.
====================
We/PRP
analyzed/VBD
whole-exome/DT
sequencing/NN
data/NNS
of/IN
matched/VBN
tumor/NN
and/CC
normal/JJ
DNA/NN
from/IN
the/DT
patients/NNS
./.
====================
The/DT
mean/JJ
coverage/NN
depth/NN
for/IN
all/DT
samples/NNS
is/VBZ
demonstrated/VBN
in/IN
Supplementary/JJ
Table/JJ
1/CD
./.
====================
In/IN
total/JJ
,/,
274/CD
somatic/JJ
mutations/NNS
in/IN
protein-coding/VBG
regions/NNS
were/VBD
called/VBN
by/IN
both/CC
callers/NNS
,/,
Strelka/NN
and/CC
Mutect/NN
./.
====================
The/DT
average/JJ
number/NN
of/IN
somatic/JJ
mutations/NNS
per/IN
case/NN
was/VBD
34/CD
,/,
showing/VBG
a/DT
range/NN
of/IN
25/CD
to/TO
59/CD
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
We/PRP
found/VBD
two/CD
patients/NNS
harboring/VBG
activating/VBG
mutations/NNS
in/IN
KRAS/JJ
,/,
such/JJ
as/IN
G12V/NN
and/CC
G13D/NN
(/(
Table/JJ
2/CD
)/)
./.
====================
Missense/NN
mutations/NNS
in/IN
codon/NN
61/CD
of/IN
the/DT
NRAS/NN
gene/NN
and/CC
codon/NN
766/CD
of/IN
the/DT
NTRK1/NN
gene/NN
were/VBD
also/RB
detected/VBN
in/IN
two/CD
patients/NNS
./.
====================
A/DT
nonsense/JJ
mutation/NN
in/IN
TP53/NN
was/VBD
found/VBN
in/IN
a/DT
patient/NN
,/,
and/CC
APC/NN
was/VBD
inactivated/VBN
by/IN
frameshift/NN
mutations/NNS
in/IN
two/CD
patients/NNS
./.
====================
A/DT
patient/NN
harbored/VBD
a/DT
frameshift/NN
mutation/NN
that/IN
was/VBD
caused/VBN
by/IN
a/DT
deletion/NN
of/IN
G/NN
in/IN
the/DT
ARID1A/NN
gene/NN
./.
====================
Detailed/JJ
information/NN
on/IN
the/DT
somatic/JJ
mutations/NNS
is/VBZ
provided/VBN
in/IN
Supplementary/JJ
Table/JJ
2/CD
./.
====================
This/DT
study/NN
analyzed/VBD
somatic/JJ
mutations/NNS
using/VBG
WES/NN
in/IN
a/DT
limited/JJ
number/NN
of/IN
patients/NNS
with/IN
BTC/NN
./.
====================
To/TO
understand/VB
the/DT
genetic/JJ
features/NNS
of/IN
BTC/NN
,/,
more/RBR
data/NNS
need/VBD
to/TO
be/VB
analyzed/VBN
from/IN
more/RBR
patients/NNS
./.
====================
Somatic/JJ
mutation/NN
count/NN
for/IN
patients/NNS
with/IN
biliary/JJ
tract/NN
cancer/NN
./.
====================
Demographic/JJ
information/NN
for/IN
patients/NNS
with/IN
BTC/NN
====================
Somatic/JJ
mutations/NNS
that/WDT
were/VBD
annotated/VBN
with/IN
cancer/NN
gene/NN
census/NN
====================
